Business
Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022
WALTHAM, Mass., May 17, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and
About this update from Ardelyx, Inc.
[{"type":"text","content":"WALTHAM, Mass., May 17, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting the efficacy and safety of IBSRELA will be presented in three posters at the 2022 Digestive Disease Week Conference (DDW 2022) to be held May 21-24, 2022, in San Diego, California and virtually.\n\n \n \n \n \n \n \n\n \nArdelyx Poster Presentations:\nTitle: \nLong Term Treatment with Tenapanor Improves Abdominal Pain and Other Abdominal Symptoms Associated with IBS-C\nAbstract Number: \n3693115\nPoster Number: \nMo1396\nDate/Time: \nMay 23, 2022, from 12:30 PM to 1:30 PM PDT\nTitle:\nEffect of Tenapanor on Treatment Satisfaction, Degree of Relief, and Quality of Life for Patients with Irritable Bowel Syndrome with Constipation (IBS-C)\nAbstract Number: \n3693709\nPoster Number: \nMo1394\nDate/Time: \nMay 23, 2022, from 12:30 PM to 1:30 PM PDT\nTitle:\nTenapanor has Early Onset of Action in Treating Symptoms of Irritable Bowel Syndrome with Constipation (IBS-C) (T3MPO-1 and T3MPO-2 Trials)\nAbstract Number: \n3693673\nPoster Number: \nTu1375\nDate/Time:\nMay 24, 2022, from 12:30 PM to 1:30 PM PDT\nIn addition to the poster presentations during DDW, Ardelyx is sponsoring a Product Theater titled: IBSRELA, an Innovative Approach for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults, on May 23, 2022, from 2:30-3:15pm PT, where thought leading experts Dr. Brooks Cash and Dr. Mark Pimentel, will review the multifactorial pathophysiology of IBS-C, the novel mechanism of action of IBSRELA, and efficacy and safety data of IBSRELA from the Phase 3 clinical trial program.\nProduct Theater speakers: Brooks D. Cash, MD, FACG, AGAF, FASGE, Dan and Lillie Sterling Professor of Medicine, Chief, Gastroenterology, Hepatology, and Nutrition, UT Health Science Center at Houston McGovern Medical School, and Mark Pimental, MD, FRCP(C), Executive Director, Medically Associated Science and Technology (MAST) Program, Cedars- Sinai Medical Center, Los Angeles, CA.\nIMPORTANT SAFETY INFORMATION\nWARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS\nIBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies...